Clinical Evidence of the Effects of CBD on Cancer

My father always said to me after losing both of his parents to cancer in the late 1960’s “I know there is a cure I think the goverment is hiding it from us”. I cherish that memory of him saying that and I knew he was right. A recent review of the multi-target effects of CBD in different types of cancer indicates that CBD is a promising bioactive molecule for treating cancer. CBD has anti-tumor properties (Ligrestri et al., 2006). Thanks Dad for instilling the will to help others in me – I hope you are smiling at me from heaven.

An increased number of studies have demonstrated that CBD and other related cannabinoids have present anticancer potential both in vitro and in vivo in a multitude of animal models ( Ramer, et al., 2008).

In 2018 an 81- year- old -man who was diagnosed with lung cancer refused chemotherapy and radiation therapy and began self-administration of CBD oil. One month later the number and size medistinal lymph nodes was observed on a CT scan (Clinical.Trials.gov).

CBD in different forms and concentrations plays in a key role in a different complex mechanisms that have as a final result the blocking cancer initiation, progression, progression, and metastation in different types of cancer (Sledsinzki et al., 2018)

References

Ligrestri, A.; Moriello, A.S.; Starowicz, K.; Matias, I.; Pisanti, S.; DePetrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; DiMarzo, V. Anti tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 2006, 318, 1375-1387.

Ramer, R,; Hinz. B.; Cannabinoids as Anticancer Drugs. Cannabinoid Pharmaclogy. Adv. Pharmacol. 2008. 153, 199-215.

Sledsinzki, P.; Zetland, J.; Slomski, R.; Nowak, A.; The current state and future perspectives of cannabinoids in cancer biology. Cancer Med. 2018, 7, 765-775.

CBDV and Autism

The Phytocannabinoid CBDV and Autism Treatments

Enzymatic conversion of cannabidivaric acid produces the phytocannabinoid cannabidivarin (CBDV). More than 100 phytocannabinoids across 11 chemical classes have been isolated and identified to date.

Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioural and physiological symptoms. RTT is caused by mutations in the MECP2 gene in about 95% of cases and to date no cure is available. The endocannabinoid system modulates several physiological processes and behavioural responses that are impaired in RTT.

Recent research suggests that CBDV was shown to reduce motor impairments and cognitive deficits in animal models of Rett syndrome, a condition that to some degree overlaps with autism, raising the possibility that CBDV might have therapeutic potential in autism spectrum disorder (ASD). 

Valproate is used for the treatment of epilepsy and other neuropsychological disorders and may be the only treatment option for women of childbearing potential. The sudy investigated the ability of CBDV to reverse or prevent ASD-like behaviors in male rats prenatally exposed to valproic acid.

Cannabidvirin in symptomatic rats recovered social impairments, social novelty preference, short-term memory deficits, repetitive behaviors and hyperlocomotion whereas preventative treatment reduced sociability and social novelty deficits, short-term memory impairments and hyperlocomotion.

These data in this paper provides preclinical evidence in support of the ability of cannabidvirin to behavioral abnormalities resembling core and associated symptoms of ASD. At the neurochemical level, symptomatic CBDV restores hippocampal endocannabinoid signaling and neuroinflammation induced by prenatal valproate.

CBD and Autism

CBD and Autism

A paper analyzing recent peer-reviewed literature to identify the current state of evidence regarding CBD use for those affected by autism. At this time, three large-scale clinical trials are currently at varying stages of progress and publication of results. Only five small studies were identified that have specifically examined cannabis use and autism. Studies which examined effects of cannabis on shared symptoms of autism such as hyperactivity, sleep disorders, self-injury, anxiety, behavioral problems, and communication were also reviewed.

Five research studies exist which have examined the direct effects of medical cannabis in individuals with autism. The most recently published study conducted in Israel, examined the safety and efficacy of medical cannabis use amongst 188 patients . Patients were treated using cannabis oil (1.5% THC and 30% CBD), and functional activities of daily living, mood, and quality of life were assessed using structured. A third of participants reported significant improvements (Schleider et al., 2019)

With a focus on behavioral problems in children and youth with autism, researchers in Jerusalem are studying the efficacy of a cannibinoid mix, while also examining safety and tolerance. The study is a double-blind randomized placebo-controlled trial and the cannabinoid mix consists of a 20:1 ratio in a 160/ 8.0 mg per ml of CBD/THC olive oil-based solution . Results from this clinical trial are eagerly anticipated

There is an urgent need for additional controlled studies to increase understanding of risks and benefits and also to examine the impact of “entourage effects.” These additional studies would support discussions of treatment options between health care providers and autism patients and their families.

References

Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019;9:200.

Biological effects of lesser known Phytocannabinoids

Of the 100+ phytochemicals that are found in the cannabis plant, we only really have evidence on the biological and potential therapeutic effects of THCA, THCV, CBDA, CBV, CBG and CBC. Of these, only THCV (in diabetes and metabolic disorders) and CBDV (in epilepsy and autism) have been tested as single molecules in humans. From animal and cell line studies, we know that THCA, THCV, and CBDA may have a role in reducing nausea. CBG might also help stimulate appetite. As these compounds are not psychotropic, they may be preferential to THC, which patients often use for nausea and appetite stimulation in cancer and HIV. THCA, THCV, CBG and CBC all have anti-inflammatory properties in various models, with therapeutic applications against a wide range of inflammatory disorders. CBDA, CBG and CBC have potential anti-tumoral properties. THCV and CBG might also be protective in various neurological disorders. Much further research is require to translate some of these promising findings into clinical trials to prove effectiveness of these compounds either as single compounds or as combinations of phytocannabinoids, in humans.

CBD and the NFL

Chris Long uses CBD and thinks the NFL should allow it. “I just think it’s dumb I think it’s arbitrary,” He said, alluding to people’s objectionable views on cannabis use. “You’re tarnishing the brand and popularity of some guys who could be great stars in the league, but you’re making them these poster children for the devil’s lettuce when you pop them with a test. It’s pointless.”

Long is no stranger to talking about weed. In May 2019 interview on “The Dan Patrick Show,” shortly after announcing his retirement after 11 seasons in the NFL, he opened up about his cannabis use, stating, “I certainly enjoyed me fair share on a regular basis through my career.”


Terrell Davis a former Hall of Fame Running back also endorses CBD use for NFL Players and believes CBD use would have extended his career.

In an interview with TMZ Sports published on Thursday, Davis noted that he feels CBD would have lessened the toll that playing football took on his body:

Former Patriots tight end Rob Gronkowski said that CBD has helped him immensely and he wants the same opportunities for friends and teammates.

“I believe so, because any time you can help your body heal—you can take out the swelling, the inflammation and you can do it in a way that’s natural—I feel like absolutely it would have assisted in that,” Davis said.

The NFL’s policy on weed continues to lag behind the times. Players who fail an initial drug test are placed in an “intervention program.” Future failed tests thereafter can result in suspensions.

And this year, the National Football League Players’ Association partnered with the NFL to study marijuana and CBD as alternatives to other pain therapies, namely opioids.

Rob Gronkowski promoting his CBD company.

CBG – Promising Effects on Depression and Anxiety

Cannabigerol (CBG) was first discovered by scientists in 1964 as a component of hashish. CBG belongs to the non-psychoactive group of cannabinoids. Research into its medical properties is currently ongoing. Though it has not been studied as intensively as the other cannabinoids like CBD or THC, results obtained so far from studies suggest that it is enriched with loads of health benefits for the consumer.

Treatment for depression and anxiety: It has been proven that THC can have positive effects on patients suffering from depression. CBG has shown similar effects but without the accompanying psychotic effects that THC is known for. A 2016 report has suggested that CBG and other non-psychotic cannabinoids could effectively treat depression and anxiety.

CBG reduces inflammation by acting on special molecules that trigger the inflammatory processes in many disease states such as cancer, inflammatory bowel disease, and pain syndromes.

CBG is a cannabinoid with particular medical properties that may have beneficial health benefits for people suffering from a variety of diseases and disorders. It is apparent that with more research, development, and education, cannabinoids such as CBG, could offer safer, more natural disease-targeted alternatives to conventional treatments. 

References

Cannabigerol. https://chem.nlm.nih.gov/chemidplus/sid/0025654313

ChemIDplus Chemical Information Classification

https://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp

Ranja, AG.; Carrillo-Salinas, F.; Pagani, A.; Gómez-Cañas, M.; Negri, R.; Navarrete, C.; Mecha, M.; Mestre, L.; Fiebich, BL.; Cantarero, I.; Calzado, MA.; Bellido, ML.; Fernandez-Ruiz, J.; Appendino, G.; Guaza, C.; Muñoz, E. (2012). “A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis”. J Neuroimmune Pharmacol. 7 (4): 1002–16. doi:10.1007/s11481-012-9399-3PMID22971837.

Hala N. Eisohly, Carlton E. Turner, Alice M. Clark, Mahmoud A. Eisohly (1982). Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds

George ANASTASSOV, Lekhram Changoer (2014). Oral care composition comprising cannabinoids


One Farm’s Experience No-Tilling CBD Hemp

No-tiller David Groff from Cedar Meadow Farm in Holtwood, Pa., talks about the farm’s experience this year no-tilling hemp and the cover-crop mix and fertility plan they followed during the growing season. He also talks about the effect weeds and vegetation had on insect pests targeting their crop.